vision study update on benefit of lu-psma | david vanderweele, md | asco22 prostate cancer updates
Published 2 years ago • 50 plays • Length 0:23Download video MP4
Download video MP3
Similar videos
-
4:48
vision: lu-177-psma-617 in mcrpc
-
3:56
vision: 177lu-psma-617 in psma-positive mcrpc
-
3:03
vision: tolerability of 177lu-psma-617 by treatment exposure in patients with mcrpc
-
7:14
vision study
-
6:45
177lu-psma-617 for prostate cancer: therap, vision, upfrontpsma and lutectomy
-
14:05
lutetium 177 psma - problems with the vision trial
-
6:43
does sugar feed prostate cancer? does fatty/adipose tissue attract cancer? | mark moyad, md, mph
-
8:58
prostadine reviews and consumer reports, explained
-
8:49
limitations of lutetium-177-psma & addressing treatment challenges
-
5:37
177lu-psma-617 for the early treatment of prostate cancer
-
11:07
phase 3 vision study of 177lupsma 617 for metastatic castration-resistant prostate cancer
-
11:49
lutetium-177 (pluvicto) vs. psma-actinium | #markscholzmd #alexscholz #pcri
-
0:29
key findings from phase i/ii study: fractionated lu-177 psma therapy shows safety and promise
-
10:07
new fda approved: pluvicto (lutetium-177) for advanced prostate cancer | mark scholz, md | pcri
-
5:05
a look at lutetium-177-psma & analyzing the vision study
-
6:24
phase iii study of lutetium-177-psma-617 in patients with metastatic castration-resistant prosta...
-
0:54
predicting 177lu-psma-617 in men with prostate cancer with nomograms
-
1:17
prince: 177lu-psma-617 and pembrolizumab in prostate cancer
-
5:06
efficacy of lutetium-177–psma-617 for advanced prostate cancer
-
10:28
anzup therap study (lu-177 psma-617 vs. cabazitaxel): overall survival after 3 years follow-up
-
0:59
dr. fendler on rationale for creating the 68ga-psma-11 pet in prostate cancer